Related Experiment Video
Updated: Jun 15, 2026

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
Foresight in medicine: current challenges with Haemophilus influenzae type b conjugate vaccines
1National Institute for Health and Welfare, FI-00271 Helsinki, Finland. juhani.eskola@thl.fi
Abstract:
An effective vaccine to prevent invasive infections caused by Haemophilus influenzae type b (Hib) bacteria has been available for more than 20 years. Hib conjugate vaccine is safe, efficacious and easy to use, and its cost-benefit ratio is high both in industrialized as well as in developing countries. In spite of this, WHO estimates that every year approximately 8 million children contract life-threatening Haemophilus infections, especially meningitis or severe pneumonia. If we want to take seriously the Millenium Development Goal of reducing the mortality of under 5-year-old children by two-thirds before the year 2015, an effective means to contribute to this would be more efficient use of Hib vaccines.
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Vaccinations
Bacterial Meningitis I: Introduction
Bacterial Meningitis
Smallpox
Poliomyelitis

